Trastuzumab Rezetecan for Injection

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Conditions

Triple Negative Breast CancerUnresectable Locally Metastatic Breast CancerUnresectable Locally Recurrent Breast Cancer

Phase 2

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

RecruitingNCT07497386

Jiangsu HengRui Medicine Co., Ltd.Unresectable Locally Metastatic Breast Cancer, Unresectable Locally Recurrent Breast Cancer

Start: 2026-04-28End: 2028-12-01Target: 150Updated: 2026-05-11

Phase 3

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

Not yet recruitingNCT07679360

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Triple Negative Breast Cancer

Start: 2026-07-01End: 2032-12-01Target: 1000Updated: 2026-07-01